An interventional study of Sampling of suspected skin lesions (in accordance with good care practices). and Constitution of a biobank in Basal Cell Carcinoma of Skin, Site Unspecified, Epidermoid Carcinoma and Lynch Syndrome, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Carcinoma, Basal Cell with a site in France — 7 open to participants now, 8 under way, 1 of them phase 3. Carcinoma, Basal Cell · France.
Among the 33 studies in Carcinoma, Basal Cell with a site in France, this one is the 8th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, and was the 32nd registered.
389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.
Browse Carcinoma, Basal Cell studies →7 of the 33 studies in Carcinoma, Basal Cell with a site in France are open now. Recruiting first, the newest first:
Hôpital NOVO · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
Philogen S.p.A. · Sites in France, Italy, Spain
Ages 18–100
Marengo Therapeutics, Inc. · Sites in France, United States, Canada and 1 more country
Ages 18+
Alpha Tau Medical LTD. · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 5 · Phase 4 1
First in 1999; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 50 across 272 interventional studies indexed under Carcinoma, Basal Cell.
Median enrollment 111 across the 23 interventional studies, 158 across the 10 observational. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 33 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
Centre Hospitalier Universitaire de Nīmes has 1 study filed under Carcinoma, Basal Cell — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma, Basal Cell with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07201012Centre Hospitalier Universitaire de NīmesDetermining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome | 2026-11 |
| NCT04068155Alpha Tau Medical LTD.Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors | 2027-01 |
| NCT07257094Hôpital NOVONasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Rehabilitation Following Nasal Skin Cancer | 2027-07-30 |
| NCT05592626Marengo Therapeutics, Inc.A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 33 studies in Carcinoma, Basal Cell with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to determine the prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome (LS) confirmed by genetic analysis. Other aims include describing the dermatological clinical manifestations of these patients in order to describe any possible new cutaneous manifestations of this syndrome. Another aim is to use molecular biology (microsatellite instability) and immunohistochemistry to analyze non-sebaceous skin lesions and deep-seated tumors that do not belong to the narrow spectrum of Lynch syndrome, and determine whether their occurrence in these patients is related to the genetic syndrome. The follow-up of these tumors (screening for new tumors) in patients with SL, as recommended by the learned societies, will also be evaluated. Finally, a biobank of cutaneous and deep tumour lesions in paraffin (retrospective) and smears of cutaneous lesions and healthy tissue (prospective) will be set up.
Muir-Torre Syndrome (MTS) is an autosomal dominant disease described independently by Muir et al. in 1967 and Torre in 1968, defined by the association of a visceral tumor of the Lynch spectrum (colorectal, endometrial, urinary excretory tract, biliary tract, small intestine, stomach or glioblastoma carcinomas) and sebaceous skin tumors and/or multiple keratoacanthomas.
Histo-molecular examination of tumors for TMS/SL is based on 2 techniques, each focusing on a different aspect of TMS pathophysiology.
Immunohistochemistry (IHC) studies the presence of proteins from the MisMatch Repair (MMR) system in lesional tissues, and an absence of expression of one of these proteins is the physical translation of an abnormality in the MMR pathway, for which the presence of a constitutional mutation in one of the MMR system genes (MLH1, PMS2, MSH2, MSH6) is responsible. An IHC-deficient MMR phenotype (dMMR) results in a complete loss of expression of one or more MMR proteins in tumor cells, with expression maintained in "normal" cells (connective cells, immune cells, non-tumor epithelial cells).
Molecular biology or microsatellite instability (MSI) testing focuses on the molecular repercussions of MMR pathway failure. The aim of this technique is to determine the presence of microsatellite marker instability in tumor tissue. While for colorectal tumors, a comparative analysis of the patient's healthy tissue can be dispensed with, for other organs on the Lynch spectrum, including sebaceous tumors, a comparison with DNA from normal tissue can help interpret the results.
The incidence of TMS among patients with genetically proven SL is poorly known. Two studies have shown a prevalence of 9.2%, both involving American patients (1,2). These were 2 retrospective chart-based studies, the skin tumors not having been re-read for diagnostic confirmation.
These patients may also develop skin tumors not belonging to the SMT-SL spectrum, such as basal cell carcinomas (BCCs), squamous cell carcinomas (SCCs) or melanocytic tumors (melanomas and nevi). These skin and deep tumors (visceral tumors) not belonging to the Lynch spectrum of patients with proven SL have rarely been systematically studied for a dMMR phenotype.
French societies (INCa, Société Française de Gastroentérologie) have proposed the management of any patient with a mutation in one of the MMR system genes. Compliance with follow-up is a major public health issue. Digestive follow-up (regular colonoscopies) is only 68%, whereas gynecological follow-up is only 73% to 80%. Other types of follow-up, notably dermatological, have rarely been analyzed, and above all we have no data on compliance in France.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Sampling of suspected skin lesions (in accordance with good care practices). · Genetic: Constitution of a biobank
Sampling of suspected skin lesions (in accordance with good care practices) and swabbing of skin microbiota.
Collection of previously excised cutaneous and deep tumour lesions kept in a public or private pathological anatomy facility for these patients
Prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome
Proportion of patients with Muir-Torre Syndrome confirmed by the occurrence of a sebaceous tumor (sebaceous adenoma, sebaceoma, sebaceous carcinoma) or several keratoacanthomas among patients with Lynch Syndrome. These tumors may or may not have had the mismatch repair system analyzed by immunohistochemistry (analysis of the 4 antibodies MLH1, PMS2, MSH2, MSH6) or by molecular biology (search for microsatellite instability). If the mismatch repair system has been studied, it must be deficient and the proteins absent on immunohistochemistry must be consistent with the mutated gene in Lynch Syndrome. If a block or slides are still available, sebaceous skin tumors or keratoacanthomas will be re-evaluated at Nîmes University Hospital for confirmation of the diagnosis.
Time frame: Up to 6 months after inclusion
Dermatological clinical manifestations in patients with confirmed Lynch Syndrome
Presence of clinical dermatological signs associated with Lynch syndrome. YES/NO
Time frame: Up to 6 months after inclusion
Non-sebaceous skin lesions and Deep-seated tumors not belonging to the narrow spectrum of Lynch syndrome. Presence of antibody MLH1
Molecular analysis (MSI test) and immunohistochemical analysis. Presence of antibody MLH1 on other tumour tissues (YES/NO) to determine the mismatch repair deficient (or MSI = pathological) or proficient (or MSS = normal) status of these lesions (and thereby their link with Muir-Torre syndrome).
Time frame: Up to 6 months after inclusion
Non-sebaceous skin lesions and Deep-seated tumors not belonging to the narrow spectrum of Lynch syndrome. Presence of antibody PMS2
Molecular analysis (MSI test) and immunohistochemical analysis. Presence of antibody PMS2 on other tumour tissues (YES/NO) to determine the mismatch repair deficient (or MSI = pathological) or proficient (or MSS = normal) status of these lesions (and thereby their link with Muir-Torre syndrome).
Time frame: Up to 6 months after inclusion
Non-sebaceous skin lesions and Deep-seated tumors not belonging to the narrow spectrum of Lynch syndrome. Presence of antibody MSH2
Molecular analysis (MSI test) and immunohistochemical analysis. Presence of antibody MSH2 on other tumour tissues (YES/NO) to determine the mismatch repair deficient (or MSI = pathological) or proficient (or MSS = normal) status of these lesions (and thereby their link with Muir-Torre syndrome).
Time frame: Up to 6 months after inclusion
Non-sebaceous skin lesions and Deep-seated tumors not belonging to the narrow spectrum of Lynch syndrome. Presence of antibody MSH6
Molecular analysis (MSI test) and immunohistochemical analysis. Presence of antibody MSH6 (YES/NO) on other tumour tissues, to determine the mismatch repair deficient (or MSI = pathological) or proficient (or MSS = normal) status of these lesions (and thereby their link with Muir-Torre syndrome).
Time frame: Up to 6 months after inclusion
Constitution of a biobank
Collection of previously excised cutaneous and deep tumour lesions kept in a public or private pathological anatomy facility for these patients
Time frame: Up to 6 months after inclusion
Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.
Of 50 interventional studies with no phase under Carcinoma, Basal Cell, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 64. This study's planned 8 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nīmes →